Augmenix Announces First Commercial Use Of SpaceOAR(TM) System For Prostate-Rectum Separation In Prostate Cancer Patients
Augmenix, Inc. has announced that Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company’s CE Mark approved SpaceOARâ„¢ System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues. Since the prostate lies directly over the rectum, prostate radiation treatment always results in some rectal radiation which can lead to pain, rectal bleeding, urgency, and other serious complications.
Read the full story here







